NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 CRNC
Cerence
-- 19.330 RGTI
Rigetti Computing
-- 19.0200 RIVN
Rivian Automotive
-- 16.490 
NEWS
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals (NASDAQ:CNSP)presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between treatment arms. Key findingsshow higher study completion rates in the Berubicin arm (84.7% vs 78.9%) and lower withdrawal rates (11.0% vs 19.7%) compared to Lomustine. Safety profiles were similar between arms, with Berubicin showing slightly higher rates of anemia and neutropenia, while Lomustine had more thrombocytopenia cases. The company expects to report primary analysis data in the first half of 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment